
Bioporto A/S
CSE:BIOPOR

Bioporto A/S
Net Change in Cash
Bioporto A/S
Net Change in Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Bioporto A/S
CSE:BIOPOR
|
Net Change in Cash
kr6.4m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
![]() |
Genmab A/S
CSE:GMAB
|
Net Change in Cash
-kr5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Zealand Pharma A/S
CSE:ZEAL
|
Net Change in Cash
kr31m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
-19%
|
|
![]() |
Ascendis Pharma A/S
NASDAQ:ASND
|
Net Change in Cash
€167.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-12%
|
CAGR 10-Years
18%
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Net Change in Cash
-kr35.5m
|
CAGR 3-Years
46%
|
CAGR 5-Years
32%
|
CAGR 10-Years
-29%
|
|
![]() |
Saniona AB
STO:SANION
|
Net Change in Cash
-kr8m
|
CAGR 3-Years
67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Bioporto A/S
Glance View
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

See Also
What is Bioporto A/S's Net Change in Cash?
Net Change in Cash
6.4m
DKK
Based on the financial report for Sep 30, 2024, Bioporto A/S's Net Change in Cash amounts to 6.4m DKK.
What is Bioporto A/S's Net Change in Cash growth rate?
Net Change in Cash CAGR 5Y
-21%
The average annual Net Change in Cash growth rates for Bioporto A/S have been -43% over the past three years , -21% over the past five years .